HOME >> BIOLOGY >> NEWS
Stem cell therapy rescues motor neurons in ALS model

MADISON -- In a study that demonstrates the promise of cell-based therapies for diseases that have proved intractable to modern medicine, a team of scientists from the University of Wisconsin-Madison has shown it is possible to rescue the dying neurons characteristic of amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disorder also known as Lou Gehrig's disease.

The new work, conducted in a rat model and reported today (July 31) in the online, open-access journal from the Public Library of Science, PLoS ONE, shows that stem cells engineered to secrete a key growth factor can protect the motor neurons that waste away as a result of ALS. An important caveat, however, is that while the motor neurons within the spinal cord are protected by the growth factor, their ability to maintain connections with the muscles they control was not observed.

"At the early stages of disease, we saw almost 100 percent protection of motor neurons," explains Clive Svendsen, a neuroscientist who, with colleague Masatoshi Suzuki, led the study at UW-Madison's Waisman Center. "But when we looked at the function of these animals, we saw no improvement. The muscles aren't responding."

At present, there are no effective treatments for ALS, which afflicts roughly 40,000 people in the United States and which is almost always fatal within three to five years of diagnosis. Patients gradually experience progressive muscle weakness and paralysis as the motor neurons that control muscles are destroyed by the disease. The cause of ALS is unknown.

In the new Wisconsin study, nascent brain cells known as neural progenitor cells derived from human fetal tissue were engineered to secrete a chemical known as glial cell line derived neurotrophic factor (GDNF), an agent that has been shown to protect neurons but that is very difficult to deliver to specific regions of the brain. The engineered cells were then implanted in the spinal cords of rats afflicted w
'"/>

Contact: Clive Svendsen
svendsen@waisman.wisc.edu
608-265-8668
University of Wisconsin-Madison
31-Jul-2007


Page: 1 2

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Study identifies new gene therapy tools for inherited blindness
7. Breast cancer and hormone therapy -- A looking-glass mirror?
8. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
9. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
10. Scientists follow familiar TRAIL to new cancer therapy
11. Complementary therapy for infertile women may reduce chances of pregnancy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:7/1/2020)... ... 2020 , ... Catalent, a global leader in clinical supply ... facility in Minakuchi, located in the Shiga prefecture of Japan. , Operating in ... new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... for biopharmaceutical R&D, today announced that it has entered into a multi-year ... antibodies (Multiclonics®), to support their translational and clinical research strategy to discover ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... 09, 2020 , ... In most research using the zebrafish ... formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the ... using the zebrafish model to investigate the causes of leukaemia and its relationship ...
(Date:7/7/2020)... ... July 06, 2020 , ... ... from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, ... has hosted an elite awards program, highlighting outstanding examples of how technology innovations ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... data insights, today announced that the launch of a new clinical ... data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service ...
(Date:6/28/2020)... Conn. (PRWEB) , ... June 25, 2020 , ... ... formed to advance photodynamic therapy for treating cancer, today announced the company has ... York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell ...
Breaking Biology Technology:
Cached News: